BioPharma Resources

Drug Trial Radar · NCT05184335

Safety and Efficacy of Brilaroxazine (RP5063) in Schizophrenia

Phase 3, Randomized, 28 Days, Double-blind, Placebo-controlled, Multicenter Study to Assess the Safety and Efficacy of Brilaroxazine (RP5063) in Subjects With Schizophrenia, Followed by a 52-Week Open-label Extension

Last checked: Nov 19, 2026Latest source record: Dec 19, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 690 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

690

Planned (sponsor's estimate)

Start

Jan 24, 2022

Primary completion

Feb 2025

Study completion Feb 2025

Sponsor

Lead sponsor
Reviva PharmaceuticalsIndustry
Sponsor type
Industry
First posted
Jan 11, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This study is to evaluate the effect and safety of Brilaroxazine in patients with acute schizophrenia compared to the placebo short and long-term. Brilaroxazine will be given at fixed doses of 15 mg or 50 mg once daily over 4 weeks, then in the long-term flexible doses 15-50mg daily over a period of 52 weeks.

Conditions

  • Schizophrenia

Interventions

  • BrilaroxazineDrug

    RP5063, a new chemical entity (NCE), is a novel multimodal neuromodulator intended for treating schizophrenia and comorbid conditions. This drug is an investigational drug and has not been approved for treatment or marketing. RP5063 belongs to a class of third generation antipsychotics called Dopamine-Serotonin System Stabilizers. The chemical name of the RP5063 active pharmaceutical ingredient (API) is 6-(4-(4-(2,3-dichlorophenyl)-piperazin-1-yl)-butoxy)-2H-benzo\[b\]\[1,4\]oxazin-3(4H)-one hydrochloride.

  • PlaceboOther

    RP5063 matching Placebo

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Double Blind Safety and Efficacy of Brilaroxazine (RP5063)Time frame: 28 days
  2. Open label Safety and Efficacy of Brilaroxazine (RP5063)Time frame: 52 weeks

Locations

18 sites in 1 country. Site status is shown where the registry gives one.

  • Reviva site

    Phoenix, Arizona · Recruiting

  • Reviva site

    Bentonville, Arkansas · Recruiting

  • Reviva site

    Little Rock, Arkansas · Recruiting

  • Reviva site

    Rogers, Arkansas · Recruiting

  • Reviva site

    Garden Grove, California · Recruiting

  • Reviva site

    Lemon Grove, California · Recruiting

  • Reviva site

    Riverside, California · Recruiting

  • Reviva site

    Hollywood, Florida · Recruiting

  • Reviva site

    Hollywood, Florida · Recruiting

  • Reviva site

    Miami Lakes, Florida · Recruiting

  • Reviva site

    Atlanta, Georgia · Recruiting

  • Reviva site

    Decatur, Georgia · Recruiting

  • Reviva site

    Chicago, Illinois · Recruiting

  • Reviva site

    Gaithersburg, Maryland · Recruiting

  • Reviva site

    Boston, Massachusetts · Recruiting

  • Reviva site

    Oklahoma City, Oklahoma · Recruiting

  • Reviva site

    Austin, Texas · Recruiting

  • Reviva site

    Richardson, Texas · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.